Merus (MRUS) Gains Validation With Zenocutuzumab Approval, Barclays Sees Growth Potential

Merus N.V. (NASDAQ:MRUS) ranks among the best biotech stocks to buy. On September 17, Barclays began coverage of Merus N.V. (NASDAQ:MRUS) with a price target of $112 and an Overweight rating. Barclays pointed out that the approval of zenocutuzumab for rare malignancies has commercially validated Merus’s platform. Source: Pixabay According to Barclays, Merus’s Phase 3 clinical asset, petosemtamab, is being investigated through two potentially registration-enabling Phase 3 trials for frontline and previou ...